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Abstract
Background: High serum resistin levels have been associated with kidney dysfunction. Most of these studies have been
carried out in individuals with severe kidney impairment, diabetes, cardiovascular disease and related treatments. Thus, the
observed association might have been influenced by these confounders. Our aim was to study the relationship between
serum resistin, urinary albumin/creatinine ratio (ACR) and glomerular filtration rate (GFR) in a family-based sample, the
Gargano Family Study (GFS) of 635 non diabetic, untreated Whites.
Methods: A linear mixed effects model and bivariate analyses were used to evaluate the phenotypic and genetic relations
between serum resistin and both ACR and eGFR. All analyses were adjusted for sex, age, age squared, BMI, systolic blood
pressure, smoking habits and physical exercise.
Results: After adjustments, resistin levels were slightly positively associated with ACR (b6SE=0.04960.023, p=0.035) and
inversely related to eGFR (b6SE=21.4360.61, p=0.018) levels. These associations remained significant when either eGFR
or ACR were, reciprocally, added as covariates. A genetic correlation (rg=20.3160.12; adjusted p=0.013) was observed
between resistin and eGFR (but not ACR) levels.
Conclusion: Serum resistin levels are independently associated with ACR and eGFR in untreated non-diabetic individuals.
Serum resistin and eGFR share also some common genetic background. Our data strongly suggest that resistin plays a role
in modulating kidney function.
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Introduction
Kidney dysfunction is a worldwide public health concern and a
major risk factor for end-stage renal disease, cardiovascular events
and premature death [1]. Identifying and treating risk factors for
this abnormality may be a valuable approach to prevent such
devastating clinical outcomes [1]. Insulin resistance, inflammation
and endothelial dysfunction have been recognized, among other
factors, as prime movers of kidney dysfunction [2,3,4]. Recently,
new molecules, secreted by adipose tissue and known as
adipokines, have been linked to all the above mentioned
conditions [5]. Among these is resistin, a 12.5 kDa cysteine-rich
protein which is also abundantly secreted by macrophages [6].
High serum resistin levels have been associated with kidney
dysfunction, including low glomerular filtration rate (GFR) and
increased albuminuria, in several studies [7,8,9,10,11,12,13].
However, most of these data were obtained in cohorts with severe
kidney impairment and cardiovascular disease and with a high
proportion of diabetic patients [7,8,9,10,11,12]. Of note, the only
study in the general population was carried out in Japanese
individuals among whom, however, hypertension was highly
prevalent (i.e. almost 50%) [13]. Thus, the observed associations
might have been influenced by any of these abnormalities as well
as their related treatments (i.e. thiazolinediones, statins and anti-
hypertensive drugs), which are known to affect circulating resistin
levels [14,15,16].
The aim of the present study was to investigate the relationship
between circulating resistin levels and renal function, as assessed
by urinary albumin/creatinine ratio (ACR) and GFR in the
absence of the above mentioned confounders. To pursue this aim
a family-based sample, the Gargano Family Study (GFS) of 635
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known to interfere with glucose homeostasis, lipid profile, blood
pressure and/or to modulate resistin and ACR levels were studied.
We also addressed the issue of whether or not circulating resistin
shares a common genetic background with either trait and, if so, if
this was explained at least in part by two SNPs in the resistin gene
RETN (i.e. rs1862513 and rs3745367) that have been previously
associated with resistin levels [17,18,19].
Materials and Methods
Subjects
The GFS comprises a total of 635 non-diabetic White
individuals, from 218 families recruited in the Gargano area (an
homogeneous geographical area in Center-East Italy) examined as
previously described [18,20,21]. Briefly, subjects were examined
between 08:00 and 09:00 h after an overnight fast. Height, weight,
waist and hip circumferences, and blood pressure were measured
in duplicate, and a blood sample was drawn for biochemical
measurements and DNA extraction.
All study subjects were not treated with medications known to
interfere with glucose homeostasis, lipid profile, blood pressure
and known to modulate resistin and ACR levels.
Ethics
The study and the informed consent procedures were approved
by the local Institutional Ethic Committee IRCCS (Istituto di
Ricovero e Cura a Carattere Scientifico) ‘‘Casa Sollievo della
Sofferenza’’. All participants gave written consent.
Measurements
Plasma glucose was measured by the glucose oxidase method on
a Beckman Glucose Analyzer 2 (Beckman Coulter, Inc., Fullerton,
CA), serum insulin was measured by microparticle enzyme
immunoassay (Abbott IMx Insulin Assay, Abbott Laboratories,
Abbott Park, IL), and lipid profile (total serum cholesterol, HDL
cholesterol and serum triglycerides) were measured by enzymatic
method, Cobas, Roche Diagnostic, Welwin Garden City, Herts,
UK.
Serum resistin concentrations were measured by a commercial
ELISA kit (Bio Vendor, Brno Czech Republic). Inter- and intra-
assay coefficients of variation were 3.2–4% and 6.3–7.2%,
respectively [18].
Urinary albumin and creatinine concentrations were deter-
mined the same morning of the clinical examination on an early
morning first void sterile urine sample by the nephelometric
method (Behring Nephelometer Analyzer) and the Jaffe ` reaction-
rate method (Hitachi 737 Autoanalyzer), respectively. Elevated
urinary albumin excretion was diagnosed if the ACR was
$2.5 mg/mmol in men and $3.5 mg/mmol in women.
GFR (eGFR) was estimated by CKD-EPI creatinine formula
[22].
The insulin resistance index homeostasis model assessment
(HOMAIR) was calculated as fasting serum insulin (pmol/liter) x
fasting plasma glucose (mmol/liter)/135 [18,20,21].
Genotyping
SNPs rs1862513 and rs3745367 in the RETN gene, selected
because of their previous association with resistin circulating levels
[17,18,19] were genotyped as previously described [18]. In
addition, for the RETN gene (i.e. 1,369 bp), rs3745367 is the only
tag SNP described for CEU population (phase 2+3 HapMap
database -www.hapmap.org- February 2009). Call rate and
concordance rate were .98% and .99% respectively. Out of
635 study individuals, genotypes were available for 628 study
subjects for rs1862513 and for 627 study subjects for rs3745367.
Allele and genotype frequencies were as follows. For rs1862513, C:
68.1% and G: 31.9%; CC: 47.6%, CG: 41% and CC: 11.4%,
respectively. For rs3745367, G: 68.6% and A: 31.4%; GG: 48.2%,
GA: 40.8% and AA: 11%, respectively. Both SNPs were in
Hardy–Weinberg Equilibrium (HWE) (p.0.05).
Statistical Analysis
Data are summarized as means6SD and median (range).
Because of resistin and ACR skewness, logarithmic transformation
was performed before further analyses.
Since we aimed at unraveling possible overall genetic correla-
tion between serum resistin and kidney function that cannot be
obtained from unrelated individuals, we analyzed nuclear families
which, in contrast, allow test such hypothesis.
To determine the contribution of genetic factors to serum
resistin, the SOLAR software package (Version 4.1.7) was utilized
[23]. SOLAR performs a variance components analysis of family
data that decomposes the total variance of the phenotypes into
components that are due to genetic effects (i.e. polygenic, additive
genetic variance), measured covariates, and random environmen-
tal effects (i.e. unique, unshared environmental effects). [24] The
relative contribution of genetic factors to serum resistin is then
estimated by heritability (h
2), defined as the ratio of the genetic
variance component to the residual (after removal of covariates)
phenotypic variance. Heritability estimates, so obtained, also
include any environmental contributions to similarities in adjusted
values between relatives [24].
To assess phenotypic correlations between resistin and ACR
and GFR, we used a mixed effects model implemented in SOLAR
[23] that includes fixed and random effects. In our variance
components model, the fixed effects are the covariates (i.e. sex,
age, age squared, BMI, systolic blood pressure smoking habits and
physical exercise), to account for known variation by these factors.
The random effects are defined by partitioning the covariance
between relative pairs into additive genetic and error covariance.
The covariance structure was determined by the degree of
relatedness between each relative. This method accounts for the
dependence of the family data and provides more stringent p
values. Results were reported as linear model coefficients along
with their standard errors and p-values (b6SE, p). P values,0.05
after correction for the two comparison we made for each model,
according to Hochberg’s method [25], were considered to be
significant.
In a multivariate model, bivariate analyses were conducted to
partition the phenotypic correlation between two traits (rp) into
genetic (rg), due to shared additive genetic effects(i.e. pleiotropy)
and environmental (re, due to shared random environmental
effects) correlations [24]. Thus, the phenotypic correlation is
influenced by both the genetic and environmental correlations
where each is weighted by the proportion of variation due to genes
(genetic) and environmental factors (non-genetic), respectively.
This approach has been implemented in SOLAR [26]. The
phenotypic correlations after the familial correlation was account-
ed for are derived from the equation rp=rg!h1
2!h2
2+re ! (12h1
2)
! (12h2
2) where h1
2 and h2
2 correspond to the heritability of traits
1 and 2, respectively. Evidence of pleiotropy (i.e. a common set of
genes influencing more than one trait) is indicated by a genetic
correlation significantly different from zero. Shared environmental
factors are indicated by an environmental correlation significantly
different from zero.
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Clinical characteristics of study participants from the GFS are
shown in Table 1.
This study comprises 140 nuclear families, 75 sibships and 20
extended sibships (ranging 3–5 individuals).
As previously reported [18] in this set, after adjusting for sex,
age, age squared, smoking habits and physical exercise, serum
resistin was highly heritable, (h
2=73.760.08 P=6.05610
218).
After adjusting for sex, age, age squared, BMI, systolic blood
pressure, smoking habits and physical exercise, serum resistin
levels were slightly positively associated with ACR
(b6SE=0.04960.023, p=0.035) and inversely related to eGFR
levels (b6SE=21.4360.61, p=0.018) (Table 2).
The associations between resistin and ACR
(b6SE=0.04860.023, p=0.048) as well as that between resistin
and eGFR (b6SE=21.2460.39, p=0.0067) remained statisti-
cally significant when eGFR and ACR were reciprocally used as
additional covariates (Table 2). Similarly, results did not change
much when the insulin resistance index, HOMAIR, or the
inflammatory marker fibrinogen were also added to the model
(Table 2). All the association remained statistically significant after
Hochberg correction (Table 2).
A significant inverse genetic correlation was observed between
resistin and eGFR (rg=20.3160.12; p=0.013), but not between
resistin and ACR (data not shown).
Among the two RETN SNPs studied only SNP rs3745367,
previously associated with resistin levels in the same setting [18]
explains some phenotypic variation (1.5%) for serum resistin. By
contrast SNP rs1862513 in our sample is not associated with
resistin (p=0.73). Neither SNP rs3745367 nor SNP rs1862513
were associated with ACR (p=0.39 and p=0.56, respectively) or
eGFR (p=0.41 and p=0.53, respectively).
No significant environmental correlations were found between
resistin and kidney function traits (Table S1).
Sixty-two out of 635 individuals (9.8% of the whole sample)
were diagnosed as having hypertension (i.e. systolic blood pressure
$140 mmHg and/or diastolic blood pressure $90 mmHg).
Exclusion of these individuals did not affect any of the results
described above (data not shown).
Discussion
The main finding of our study is that serum resistin is inversely
and independently associated with eGFR and shares with it a
common genetic (but not environmental) background.
Importantly, of all the variables we had the opportunity to test
in our study, resistin is by far the most important predictor of
eGFR, accounting for 7% of its variance. Taken together, our data
suggest that resistin is a strong modulator of kidney function.
We also observed a weaker association between resistin and
ACR. However, the level of statistical significance of this
association is marginal making the relevance of this finding
uncertain.
Unfortunately we were unable to asses if the established notion
of a common genetic background between serum resistin and
GFR could be explained by some variation at the RETN locus. In
fact, of the two SNPs we investigated, the only one which was
associated with serum resistin (i.e. rs3745367), was not associated
with eGFR.
It must be emphasized that the sample that we analyzed consists
only of non-diabetic, untreated, relatively young individuals (mean
age=40 years) with normal kidney function and no clinical reports
of cardiovascular disease. Thus, our results are not influenced by
the possible confounders that may have heavily affected previous
studies addressing the role of resistin on kidney function
[7,8,9,10,11,12,13].
Table 1. Clinical characteristics of study participants of the
GFS (635 non-diabetic individuals from 218 families).
Mean±SD Median (Range)
M/F 246/389
Age (yrs) 40.1614.4 40.0 (16–82)
BMI (Kg/m
2) 26.364.7 25.5 (17.1–48.2)
Waist circumference (cm) 84.7612.5 84.0 (50–126.0)
Obese (%) 18.6
Overweight (%) 10.2
SBP (mmHg) 116.9614.5 115.0 (80–180)
DBP (mmHg) 77.169.0 80.0 (50–112)
Hypertensive (%) 9.8
FBG (mmol/L) 5.060.57 4.89 (3.20–6.99)
Insulin (pmol/L) 55.6631.9 49.3 (12.5–333.4)
HOMAIR 1.861.1 1.54 (0.36–10.0)
Triacylglycerol (mg/dL) 100.3666.1 81.0 (28.0–520.0)
HDL cholesterol (mg/dL) 52.8613.3 52.0 (21–119.0)
eGFR 87.97613.4 87 (60–184)
ACR (mg/mmol) 0.961.16 0.53 (0.06–12.4)
Fibrinogen (mg/dL) 292.8661.4 286.0 (149–591)
Resistin (ng/mL) 5.963.0 5.3 (1.2–26.8)
Data are expressed as Mean 6 SD or %.
BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood
Pressure; FBG: Fasting Blood Glucose; HOMAIR: homeostasis model assessment
of insulin-resistance; HDL-Cholesterol: high-density lipoprotein cholesterol;
eGFR: estimated Glomerular Filtration Rate by CKD-EPI formula; ACR: Albumin
Creatinine Ratio.
Obese: BMI $30.
Overweight: BMI $25#29.9.
Hypertensive: (i.e. systolic blood pressure $140 mmHg and/or diastolic blood
pressure $90 mmHg).
doi:10.1371/journal.pone.0038414.t001
Table 2. Association of serum resistin levels and renal
functions in the GFS.
ACR (mg/mmol) eGFR (mL/min)
b±SE p p* b±SE p p*
Model 1 0.04960.023 0.035 0.035 21.4360.61 0.018 0.035
Model 2 0.04860.023 0.048 0.048 21.2460.39 0.0067 0.0134
Model 3 0.04760.023 0.047 0.047 21.2660.36 0.016 0.0320
Model 4 0.04660.023 0.049 0.049 21.2960.45 0.013 0.026
The linear b coefficients represent the change in ACR and GFR levels for 1 unit
increase of serum resistin levels (ng/mL).
ACR: Albumin Creatinine Ratio; eGFR: estimated Glomerular Filtration Rate by
CKD-EPI formula.
Model 1: analyses are adjusted for sex, age, age squared, BMI, smoking habit,
physical exercise and systolic blood pressure.
Model 2: model 1 plus adjustment for eGFR or ACR when testing the association
of resistin with ACR and GFR, respectively.
Model 3: model 1 plus adjustment for HOMAIR.
Model 4: model 1 plus adjustment for plasma fibrinogen.
*P value obtained after Hochberg correction.
doi:10.1371/journal.pone.0038414.t002
Resistin and Kidney Function
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38414In addition, we choose a family-based study for our specific
purpose, because it is of note that, in general, such studies have
more statistical power and minimize the risk for population
stratification, as compared to studies carried out in unrelated
individuals [27].
Resistin has been linked both with insulin resistance and
inflammation [6]; however, our data showing that the association
between serum resistin and eGFR is not affected by either
HOMAIR or plasma fibrinogen, suggest that it is not mediated by
systemic insulin resistance or chronic low-grade inflammation. It
has been recently reported that resistin may play an important role
in potentiating endothelial dysfunction through oxidative stress
[28]. One can then speculate that resistin may have a direct
deleterious effect on the glomeruli, as shown for other adipokines
[29]. It is also possible that other, as yet unidentified systemic
pathways underlie the biology of the association between resistin
and kidney function.
This study has some limitations. We did not investigate
comprehensively the impact of RETN locus genetic variability in
modulating the common genetic background shared by resistin
and eGFR, limiting our genotyping only to two SNPs which have
been previously associated with serum resistin levels in our [18,19]
and other populations [17]. So, we cannot exclude that other
SNPs outside the RETN gene play also a role in modulating the
common genetic background between resistin and eGFR. In
addition, whether our data can be generalized to other populations
with different environmental and/or genetic background is not
known and deserves further investigation [30].
In conclusion, our study shows a strong and independent
correlation between resistin levels and GFR. The two variables
share also some common genetic background. Dissection of the
exact mechanisms underlying this relationship may help develop
tailored interventions aimed at preventing kidney function loss in
high risk individuals.
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